Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
TSHA Stock Chart & Stats
$4.58
-$0.08(-4.26%)
At close: 4:00 PM EST
$4.58
-$0.08(-4.26%)
Day’s Range― - ―
52-Week Range$1.05 - $6.02
Previous CloseN/A
Volume273.02K
Average Volume (3M)2.55M
Market Cap
$1.32B
Enterprise Value$844.15M
Total Cash (Recent Filing)$319.77M
Total Debt (Recent Filing)$18.17M
Price to Earnings (P/E)―
Beta2.46
Next Earnings
May 20, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding287,269,900
10 Day Avg. Volume3,070,032
30 Day Avg. Volume2,546,634
Financial Highlights & Ratios
PEG Ratio2.90
Price to Book (P/B)7.12
Price to Sales (P/S)179.93
P/FCF Ratio-18.74
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue86.38
Enterprise Value/Gross Profit91.88
Enterprise Value/Ebitda-7.80
Forecast
1Y Price Target
$12.11Price Target Upside164.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.44
Revenue Forecast (FY)$4.46M
Bulls Say, Bears Say
Bulls Say
Pivotal Trial Design And ReadoutsA planned six‑month interim analysis in the pivotal REVEAL Part B trial, combined with regulator‑validated powering and per‑milestone worst‑case simulations, creates a credible route to an earlier topline readout that could support a biologics license application.
Regulatory PathwayFDA agreement on the study's statistical analysis plan, allowance to include younger patients in potential labeling, and permission to pool manufacturing data reduce regulatory hurdles and strengthen the path toward approval for the lead gene therapy.
Safety Profile And Commercial DifferentiationEarly clinical safety data showing no treatment‑related serious adverse events or toxic MeCP2 overexpression, plus physician and caregiver preference for intrathecal delivery, supports confidence in safety and potential commercial uptake versus a competitor.
Bears Say
Data Availability And TimingCompany plans to release interim trial data only after a pre‑BLA meeting could delay public access to pivotal results and extend uncertainty around development milestones.
Research ObjectivityDisclosure that a major research firm may have conflicts of interest from doing business with covered companies raises concerns that published analyst reports could be biased and may weaken investor confidence.
Scientific ValidationDependence on a pre‑printed natural history study that has not completed peer review introduces risk that key assumptions may require further validation before reliably supporting trial design or regulatory decisions.
Taysha Gene Therapies News
TSHA FAQ
What was Taysha Gene Therapies’s price range in the past 12 months?
Taysha Gene Therapies lowest stock price was $1.05 and its highest was $6.02 in the past 12 months.
What is Taysha Gene Therapies’s market cap?
Taysha Gene Therapies’s market cap is $1.32B.
When is Taysha Gene Therapies’s upcoming earnings report date?
Taysha Gene Therapies’s upcoming earnings report date is May 20, 2026 which is in 55 days.
How were Taysha Gene Therapies’s earnings last quarter?
Taysha Gene Therapies released its earnings results on Mar 19, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.096 by $0.016.
Is Taysha Gene Therapies overvalued?
According to Wall Street analysts Taysha Gene Therapies’s price is currently Undervalued.
Does Taysha Gene Therapies pay dividends?
Taysha Gene Therapies does not currently pay dividends.
What is Taysha Gene Therapies’s EPS estimate?
Taysha Gene Therapies’s EPS estimate is -0.1.
How many shares outstanding does Taysha Gene Therapies have?
Taysha Gene Therapies has 287,269,900 shares outstanding.
What happened to Taysha Gene Therapies’s price movement after its last earnings report?
Taysha Gene Therapies reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.096. Following the earnings report the stock price went up 2.472%.
Which hedge fund is a major shareholder of Taysha Gene Therapies?
Currently, no hedge funds are holding shares in TSHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Taysha Gene Therapies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.11 (164.41% Upside)
$12.11 (164.41% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.79%
12-Months-Change
Fundamentals
Return on Equity
-56.64%
Trailing 12-Months
Asset Growth
75.00%
Trailing 12-Months
Company Description
Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
TSHA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical and regulatory progress — compelling Part A efficacy signals, initiation of the pivotal trial, FDA Breakthrough designation, written FDA alignments on trial designs and CMC comparability, and a clear commercial readiness plan — supported by a solid cash position into 2028. These positives are tempered by rising R&D and G&A expenses, a larger net loss in 2025, small sample sizes in key pediatric safety cohorts, and contingent regulatory timing that could require longer follow-up. On balance, the forward clinical and regulatory momentum materially outweighs the financial and operational risks discussed.View all TSHA earnings summariesTSHA Stock 12 Month Forecast
Average Price Target
$12.11
▲(164.41% Upside)
Technical Analysis
Relay Therapeutics
―
Immunome
―
ARS Pharmaceuticals
―
Sana Biotechnology
―
Prime Medicine, Inc.
―
Ownership Overview
12.88% Insiders
9.46% Mutual Funds
49.47% Other Institutional Investors
16.27% Public Companies and Individual Investors